Investor Presentaiton
Highly experienced leadership team
Clarity's management team has a diverse and in-depth level of expertise spanning corporate finance, management, operations,
commercialisation and industry
Dr Alan Taylor
Executive Chairman
Dr Colin Biggin
Managing Director,
Dr Matt Harris
Chief Scientific Officer
CEO
Michelle Parker
Director of Clinical
Operations
Dr Jennifer Rosenthal
Director of Quality and
Regulatory Affairs
Shaemus Gleason
Executive VP, US
Operations
David Green
Chief Financial Officer
Dr Taylor has been
instrumental in the growth
of the Company and has
been heavily involved in all
areas of the Company's
business. Dr Taylor has
approximately 15 years of
investment banking
experience focused
predominantly on the life.
sciences sector, and has
significant expertise in
capital raisings, mergers
and acquisitions, and
general corporate
advisory. Prior to joining
Clarity, Dr Taylor was an
Executive Director of Inteq
Limited, a boutique
Australian investment
bank.
Dr Biggin has over 15 years
of radiopharmaceutical
development and
commercialisation
experience. Dr Biggin
previously served with
Algeta ASA during the
development and
commercialisation of its
product Xofigo (radium-
223 dichloride) for
metastatic prostate
cancer, which was
approved by the FDA in
2013. Prior to joining the
Company, Dr Biggin also
consulted to a range of
biotech and large
pharmaceutical
companies developing
radiopharmaceuticals.
Dr Harris has approximately
20 years of combined
experience in cancer
research, nuclear
medicine and business
and has a PhD in cancer
research from the
Australian National
University.
Dr Harris brings expertise in
biotechnology.
radiopharmaceuticals,
academic research and
investment to the
Company and focuses on
developing the
technology behind the
Company's products.
Ms Parker has over 20
years of experience
spanning across nuclear
medicine/PET and
pharmaceutical industries
both in Australia and
internationally. Prior to
joining Clarity, Ms Parker
held the position of Head
of International Clinical
Research Operations at
Novartis Australia, a global
pharmaceutical company,
leading a multi-disciplinary,
high performing team of
over 35 associates
responsible for end-to-end
clinical trial execution.
Dr Rosenthal has over 20 years
of management experience
in the biotechnology industry,
serving in senior director and
executive level roles with an
oncology focus. She has
successfully developed
strategy, and managed
teams and projects in the
areas of regulatory affairs
(agencies include US FDA,
EMA and Australian TGA),
clinical trials, quality assurance
and IP.
Prior to joining Clarity, Dr
Rosenthal managed the
global regulatory team at the
previously ASX-listed company
Viralytics Limited, which was
acquired by Merck & Co for
$502 million in 2018. Prior to
Viralytics, Jennifer spent 10
years at Alchemia Limited,
and at Florigene and Davies
Collison Cave Patent and
Trademark Attorneys.
Mr Gleason has over 13
years of experience
spanning across all facets
of targeted radionuclide
therapies and diagnostic
radiopharmaceuticals.
Prior to joining the
Company, he was a
member of the oncology
strategy business unit at
Bayer/Algeta where he
was responsible for the
technical operations in
their phase I targeted
alpha therapy
development globally.
Prior to this, he held a
leadership role on the US
commercial organisation
supporting a marketed
product Xofigo® (radium-
223 dichloride) for
metastatic prostate
cancer.
Mr Green has over 25
years' experience in
performing senior finance
roles for listed and unlisted
companies, including
Pacific Dunlop Limited,
Sigma Pharmaceuticals,
Alchemia Limited, Chiquita
Brands South Pacific
Limited (now Costa
Group) and Ellume
Limited. As a proven CFO,
he has extensive
experience in complex
operating environments
across multiple
geographies, private
treaty and public
company transactions,
treasury operations and
debt and equity markets.
CLARITY
2014 M
31View entire presentation